IMMP - Immutep granted Chinese patent for eftilagimod alpha

Immutep (NASDAQ:IMMP) announces the grant of a new patent entitled "use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response" by the Chinese Patent Office. The patent forms part of a broad portfolio of patent families for the company’s lead product candidiate eftilagimod alpha in key global markets including China. The claims of the new patent relate to methods of use of ((a)) Immutep’s efti which is a LAG-3 fusion protein (LAG-3Ig) and ((b)) a chemotherapy agent in combination for the manufacture of a preparation for the treatment of cancer. The patent provides protection in mainland China and the expiry date is 3 October 2028. Shares up nearly 3% premarket.

For further details see:

Immutep granted Chinese patent for eftilagimod alpha